5-chloro-2,4'-dimethylbiphenyl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloro-2,4'-dimethylbiphenyl
• 英文别名: 4-Chloro-1-methyl-2-(4-methylphenyl)benzene
• 化学式: C₁₄H₁₃Cl
• 分子量: 216.71
• InChiKey: AFQURRHAGZGESY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  bis(4-methylphenyl)chloronium hexafluorophosphate 以 丙酮 为溶剂， 生成 对氯甲苯 、 2-chloro-4',5-dimethylbiphenyl 、 5-chloro-2,4'-dimethylbiphenyl 、 甲苯
  参考文献：
  名称：

  Comparison of the photochemistry of diarylchloronium, diarylbromonium, and diaryliodonium salts

  摘要：

  The direct and triplet-sensitized photochemistry of diphenylchloronium, diphenylbromonium, bis(4-methylphenyl)chloronium, and bis(4-methylphenyl)bromonium salts was studied. Direct photolysis of the diarylhalonium salts gave haloarene 2-, 3-, and 4-halobiaryls, and acetanilide, predominantly from a heterolytic cleavage mechanism via the aryl cation-haloarene pair, via in-cage recombination and cage-escape reactions. However, triplet-sensitized photolysis gave haloarene, 2-, 3-, and 4-halobiaryl, and reduced arene mainly from homolytic cleavage to the arene radical-haloarene radical cation pair, which also gave in-cage recombination and cage-escape products. There is evidence for singlet-triplet interconversion of the excited states by spin-orbit coupling and interconversion of the singlet-triplet radical pairs by spin-spin coupling. In addition, electron transfer between the singlet arene cation-haloarene and arene radical-haloarene radical cation pairs is also possible. The effect of halogen and arene substituent on these interconversions is discussed.

  DOI：

  10.1021/jo00005a033

文献信息

• [EN] GLUCAGON ANTAGONISTS<br/>[FR] ANTAGONISTES DE GLUCAGON
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2010019830A1

  公开（公告）日：2010-02-18

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co- crystals and prodrugs thereof. Formula I

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体和前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或病情的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体和前药。公式I
• SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
  申请人：Karos Pharmaceuticals, Inc.

  公开号：US20150080393A1

  公开（公告）日：2015-03-19

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及螺环化合物，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPH1），可用于治疗与外周血清素相关的疾病或疾病，例如胃肠道、心血管、肺部、炎症、代谢和低骨量疾病，以及血清素综合症和癌症。
• GLUCAGON ANTAGONISTS
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP3153501A1

  公开（公告）日：2017-04-12

  Provided herein are compounds of Formula I, where the variables are as defined herein, and pharmaceutically acceptable salts, solvates or prodrugs thereof having an optical purity of at least 95% of the R enantiomer which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well the the same for use in methods of treating, preventing or ameliorating a condition, disorder or disease for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Formula I

  本文提供了式I化合物（其中变量如本文所定义）及其药学上可接受的盐、溶液或原药，其R对映体的光学纯度至少为95%，具有胰高血糖素受体拮抗剂或反向激动剂活性。此外，本文还提供了包含相同成分的药物组合物，以及相同成分用于治疗、预防或改善一种或多种胰高血糖素受体拮抗剂适用的病症、紊乱或疾病的方法，包括 I 型和 II 型糖尿病、胰岛素抵抗和高血糖症。 式 I
• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10350208B2

  公开（公告）日：2019-07-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。
• Glucagon antagonists
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2799428B1

  公开（公告）日：2016-11-16